BACKGROUND: Lobules in normal breast tissue can be classified based on their degree of development, which may affect their susceptibility to carcinogenesis. However, few epidemiologic studies to date have addressed this. METHODS: The authors examined the association between lobule type and subsequent breast cancer risk in a nested case-control study of benign breast disease (BBD) and breast cancer within the Nurses' Health Studies (200 cases, 915 controls). Benign breast biopsy slides were reviewed by pathologists, and normal terminal duct lobular units were classified as having no type 1 lobules, mixed lobule types, or predominant type 1 and no type 3 lobules. Logistic regression was used to compute odds ratios (ORs) and 95% confidence intervals (CIs) for the association between lobule type and breast cancer risk. RESULTS: Women with predominant type 1 and no type 3 lobules (54 cases, 321 controls) had a decreased risk of breast cancer compared with those with no type 1 lobules or mixed lobule types (OR=0.63; 95% CI, 0.44-0.91), although this was attenuated after adjustment for histologic category of BBD (OR=0.71; 95% CI, 0.49-1.02). Having predominant type 1 lobules and no type 3 lobules was associated with a similar risk reduction for all categories of BBD (nonproliferative: OR=0.73 [95% CI, 0.36-1.50]; proliferative without atypia: OR=0.80 [95% CI, 0.47-1.35]; and atypical hyperplasia: OR=0.61 [95% CI, 0.28-1.35]). CONCLUSIONS: These results provided preliminary evidence that lobule type may be an important marker of breast cancer risk in women with BBD. (c) 2009 American Cancer Society
BACKGROUND: Lobules in normal breast tissue can be classified based on their degree of development, which may affect their susceptibility to carcinogenesis. However, few epidemiologic studies to date have addressed this. METHODS: The authors examined the association between lobule type and subsequent breast cancer risk in a nested case-control study of benign breast disease (BBD) and breast cancer within the Nurses' Health Studies (200 cases, 915 controls). Benign breast biopsy slides were reviewed by pathologists, and normal terminal duct lobular units were classified as having no type 1 lobules, mixed lobule types, or predominant type 1 and no type 3 lobules. Logistic regression was used to compute odds ratios (ORs) and 95% confidence intervals (CIs) for the association between lobule type and breast cancer risk. RESULTS:Women with predominant type 1 and no type 3 lobules (54 cases, 321 controls) had a decreased risk of breast cancer compared with those with no type 1 lobules or mixed lobule types (OR=0.63; 95% CI, 0.44-0.91), although this was attenuated after adjustment for histologic category of BBD (OR=0.71; 95% CI, 0.49-1.02). Having predominant type 1 lobules and no type 3 lobules was associated with a similar risk reduction for all categories of BBD (nonproliferative: OR=0.73 [95% CI, 0.36-1.50]; proliferative without atypia: OR=0.80 [95% CI, 0.47-1.35]; and atypical hyperplasia: OR=0.61 [95% CI, 0.28-1.35]). CONCLUSIONS: These results provided preliminary evidence that lobule type may be an important marker of breast cancer risk in women with BBD. (c) 2009 American Cancer Society
Authors: Laura C Collins; Heather J Baer; Rulla M Tamimi; James L Connolly; Graham A Colditz; Stuart J Schnitt Journal: Cancer Date: 2006-09-15 Impact factor: 6.860
Authors: Tia R Milanese; Lynn C Hartmann; Thomas A Sellers; Marlene H Frost; Robert A Vierkant; Shaun D Maloney; V Shane Pankratz; Amy C Degnim; Celine M Vachon; Carol A Reynolds; Romayne A Thompson; L Joseph Melton; Ellen L Goode; Daniel W Visscher Journal: J Natl Cancer Inst Date: 2006-11-15 Impact factor: 13.506
Authors: Jose Russo; Gabriela A Balogh; Jinqiang Chen; Sandra V Fernandez; Rachael Fernbaugh; Rebecca Heulings; Daniel A Mailo; Raquel Moral; Patricia A Russo; Fathima Sheriff; Johana E Vanegas; Richard Wang; Irma H Russo Journal: Front Biosci Date: 2006-01-01
Authors: L M Marshall; D J Hunter; J L Connolly; S J Schnitt; C Byrne; S J London; G A Colditz Journal: Cancer Epidemiol Biomarkers Prev Date: 1997-05 Impact factor: 4.254
Authors: Rathi Ramakrishnan; Peter H Gann; Elizabeth L Wiley; Kamal K Khurana; Seema A Khan Journal: Breast Cancer Res Treat Date: 2004-08 Impact factor: 4.872
Authors: Jonine D Figueroa; Ruth M Pfeiffer; Louise A Brinton; Maya M Palakal; Amy C Degnim; Derek Radisky; Lynn C Hartmann; Marlene H Frost; Melody L Stallings Mann; Daphne Papathomas; Gretchen L Gierach; Stephen M Hewitt; Maire A Duggan; Daniel Visscher; Mark E Sherman Journal: Breast Cancer Res Treat Date: 2016-08-03 Impact factor: 4.872
Authors: Gretchen L Gierach; Jonine D Figueroa; Clara Bodelon; Hannah Oh; Nilanjan Chatterjee; Montserrat Garcia-Closas; Maya Palakal; Mark E Sherman; Ruth M Pfeiffer; Berta Geller; Pamela Vacek; Donald L Weaver; Rachael Chicoine; Daphne Papathomas; Jackie Xiang; Deesha A Patel; Zeina G Khodr; Laura Linville; Susan E Clare; Daniel W Visscher; Carolyn Mies; Stephen M Hewitt; Louise A Brinton; Anna Maria V Storniolo; Chunyan He; Stephen J Chanock Journal: Int J Cancer Date: 2016-11-18 Impact factor: 7.396
Authors: Jonine D Figueroa; Ruth M Pfeiffer; Deesha A Patel; Laura Linville; Louise A Brinton; Gretchen L Gierach; Xiaohong R Yang; Daphne Papathomas; Daniel Visscher; Carolyn Mies; Amy C Degnim; William F Anderson; Stephen Hewitt; Zeina G Khodr; Susan E Clare; Anna Maria Storniolo; Mark E Sherman Journal: J Natl Cancer Inst Date: 2014-10-01 Impact factor: 13.506
Authors: Gertraud Maskarinec; Dan Ju; Yurii B Shvetsov; David Horio; Owen Chan; Lenora W M Loo; Brenda Y Hernandez Journal: Cancer Epidemiol Date: 2020-02-12 Impact factor: 2.984
Authors: Laura C Collins; Ninah Achacoso; Larissa Nekhlyudov; Suzanne W Fletcher; Reina Haque; Charles P Quesenberry; Balaram Puligandla; Najeeb S Alshak; Lynn C Goldstein; Allen M Gown; Stuart J Schnitt; Laurel A Habel Journal: Am J Surg Pathol Date: 2009-12 Impact factor: 6.394
Authors: Hannah Oh; Zeina G Khodr; Mark E Sherman; Maya Palakal; Ruth M Pfeiffer; Laura Linville; Berta M Geller; Pamela M Vacek; Donald L Weaver; Rachael E Chicoine; Roni T Falk; Hisani N Horne; Daphne Papathomas; Deesha A Patel; Jackie Xiang; Xia Xu; Timothy Veenstra; Stephen M Hewitt; John A Shepherd; Louise A Brinton; Jonine D Figueroa; Gretchen L Gierach Journal: Horm Cancer Date: 2016-05-02 Impact factor: 3.869
Authors: Hannah Oh; Clara Bodelon; Maya Palakal; Nilanjan Chatterjee; Mark E Sherman; Laura Linville; Berta M Geller; Pamela M Vacek; Donald L Weaver; Rachael E Chicoine; Daphne Papathomas; Deesha A Patel; Jackie Xiang; Susan E Clare; Daniel W Visscher; Carolyn Mies; Stephen M Hewitt; Louise A Brinton; Anna Maria V Storniolo; Chunyan He; Montserrat Garcia-Closas; Stephen J Chanock; Gretchen L Gierach; Jonine D Figueroa Journal: Breast Cancer Res Treat Date: 2016-06-24 Impact factor: 4.872
Authors: Fitriya N Dewi; Charles E Wood; Cynthia J Lees; Cynthia J Willson; Thomas C Register; Janet A Tooze; Adrian A Franke; J Mark Cline Journal: Cancer Prev Res (Phila) Date: 2013-06-14